CLINICAL_TRIALS
trial_result
· 2025-12-05
Clinical Trial Update: BESPONSA Injection 1 mg Special Investigation
Summary
Completed clinical trial evaluating BESPONSA (inotuzumab ozogamicin) 1 mg for acute lymphoblastic leukemia; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Acute Lymphocytic Leukemia | Status: COMPLETED | Results posted: 2025-12-05